Sovaldi

E411074
antiviral medication direct-acting antiviral hepatitis C drug

Sovaldi is a breakthrough antiviral medication used to treat chronic hepatitis C by directly inhibiting the virus’s replication.

Try in SPARQL Jump to: Surface forms Statements Referenced by

All labels observed (3)

Label Occurrences
sofosbuvir 2
Sofosbuvir 1
Sovaldi canonical 1

Statements (49)

Predicate Object
instanceOf antiviral medication ⓘ
direct-acting antiviral ⓘ
hepatitis C drug ⓘ
approvedBy Food and Drug Administration ⓘ
surface form: U.S. Food and Drug Administration
approvedIn European Union ⓘ
United States of America ⓘ
surface form: United States
belongsToClass nucleotide analog polymerase inhibitors ⓘ
boxedWarning risk of hepatitis B virus reactivation in coinfected patients ⓘ
commonAdverseEffect fatigue ⓘ
headache ⓘ
insomnia ⓘ
nausea ⓘ
contraindicatedWith amiodarone (relative contraindication due to bradycardia risk) ⓘ
developedBy Gilead Sciences (board member) ⓘ
surface form: Gilead Sciences
dosageForm film-coated tablet ⓘ
eliminationHalfLife approximately 0.4 hours for sofosbuvir ⓘ
approximately 27 hours for main metabolite GS-331007 ⓘ
FDAApprovalDate 2013-12-06 ⓘ
hasActiveIngredient sofosbuvir ⓘ
hasATCCode J05AX15 ⓘ
hasBreakthroughDesignation yes (for certain HCV indications) ⓘ
hasGenericName Sovaldi self-linksurface differs ⓘ
surface form: sofosbuvir
hasMechanismOfAction NS5B RNA-dependent RNA polymerase inhibition ⓘ
indicatedFor treatment of chronic hepatitis C in adults ⓘ
treatment of chronic hepatitis C in pediatric patients 3 years and older ⓘ
inhibits HCV NS5B RNA-dependent RNA polymerase ⓘ
surface form: HCV NS5B polymerase
isFirstInClass one of the first highly effective oral DAAs for HCV ⓘ
isProdrugOf sofosbuvir triphosphate ⓘ
marketedBy Gilead Sciences (board member) ⓘ
surface form: Gilead Sciences
metabolizedTo GS-461203 (active triphosphate) ⓘ
patentHolder Gilead Sciences (board member) ⓘ
surface form: Gilead Sciences
pregnancyCategoryUS B ⓘ
requiresMonitoring HBV coinfection status ⓘ
hepatic function ⓘ
routeOfAdministration oral ⓘ
seriousAdverseEffect severe bradycardia with amiodarone coadministration ⓘ
takenWithFood may be taken with or without food ⓘ
treats chronic hepatitis C virus infection ⓘ
hepatitis C genotype 1 ⓘ
hepatitis C genotype 2 ⓘ
hepatitis C genotype 3 ⓘ
hepatitis C genotype 4 ⓘ
hepatitis C genotype 5 ⓘ
hepatitis C genotype 6 ⓘ
typicalDose 400 mg once daily in adults ⓘ
usedInCombinationWith daclatasvir ⓘ
ledipasvir ⓘ
peginterferon alfa ⓘ
ribavirin ⓘ

Referenced by (4)

Full triples — surface form annotated when it differs from this entity's canonical label.

Gilead Sciences (board member) → product → Sovaldi ⓘ
subject surface form: Gilead Sciences
velpatasvir → usedWith → Sovaldi ⓘ
subject surface form: Velpatasvir
this entity surface form: Sofosbuvir
Harvoni → hasActiveIngredient → Sovaldi ⓘ
this entity surface form: sofosbuvir
Sovaldi → hasGenericName → Sovaldi self-linksurface differs ⓘ
this entity surface form: sofosbuvir